

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM441622

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Second Lien Security Agreement
SEQUENCE:	3

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Albany Molecular Research, Inc.		08/31/2017	Corporation: DELAWARE
AMRI Burlington, Inc.		08/31/2017	Corporation: MASSACHUSETTS
Cedarburg Pharmaceuticals, Inc.		08/31/2017	Corporation: DELAWARE
Euticals Inc.		08/31/2017	Corporation: DELAWARE
OSO Biopharmaceuticals Manufacturing, LLC-by its sole member: ALO Acquisition LLC		08/31/2017	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	Morgan Stanley Senior Funding, Inc., as the Collateral Agent
Street Address:	1300 Thames Street, 4th Floor
Internal Address:	Thames Street Wharf
City:	Baltimore
State/Country:	MARYLAND
Postal Code:	21231
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 19

Property Type	Number	Word Mark
Registration Number:	5192656	AMRI
Registration Number:	5196964	AMRI
Registration Number:	3477433	
Registration Number:	4427558	AMRI GLOBAL SMARTSOURCING
Registration Number:	4427557	AMRI GLOBAL SMARTSOURCING
Registration Number:	4911976	AMRI ALBANY MOLECULAR RESEARCH INC.
Registration Number:	4911977	AMRI ALBANY MOLECULAR RESEARCH INC.
Registration Number:	3360935	AMRI
Registration Number:	4427550	AMRI GLOBAL SMARTSOURCING

CH \$490.00 5192656

Property Type	Number	Word Mark
Registration Number:	4427548	AMRI GLOBAL SMARTSOURCING
Registration Number:	4427554	AMRI SMARTSOURCING
Registration Number:	4427553	AMRI SMARTSOURCING
Registration Number:	4427555	SMARTSOURCING
Registration Number:	4427556	SMARTSOURCING
Registration Number:	4794054	SSCI
Registration Number:	4928687	TRIADS
Registration Number:	3901048	OSOIBIO AN INJECTABLES CMO
Registration Number:	3278678	WHERE CHEMISTRY MATTERS
Registration Number:	2306495	

CORRESPONDENCE DATA

Fax Number: 2024083141

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2024083141

Email: jean.paterson@cscglobal.com

Correspondent Name: CSC

Address Line 1: 1090 Vermont Avenue, NW

Address Line 4: Washington, D.C. 20005

ATTORNEY DOCKET NUMBER: 792486

NAME OF SUBMITTER: Jean Paterson

SIGNATURE: /jep/

DATE SIGNED: 09/01/2017

Total Attachments: 31

source=9-1-17 Albany Molecular 2-TM#page1.tif
source=9-1-17 Albany Molecular 2-TM#page2.tif
source=9-1-17 Albany Molecular 2-TM#page3.tif
source=9-1-17 Albany Molecular 2-TM#page4.tif
source=9-1-17 Albany Molecular 2-TM#page5.tif
source=9-1-17 Albany Molecular 2-TM#page6.tif
source=9-1-17 Albany Molecular 2-TM#page7.tif
source=9-1-17 Albany Molecular 2-TM#page8.tif
source=9-1-17 Albany Molecular 2-TM#page9.tif
source=9-1-17 Albany Molecular 2-TM#page10.tif
source=9-1-17 Albany Molecular 2-TM#page11.tif
source=9-1-17 Albany Molecular 2-TM#page12.tif
source=9-1-17 Albany Molecular 2-TM#page13.tif
source=9-1-17 Albany Molecular 2-TM#page14.tif
source=9-1-17 Albany Molecular 2-TM#page15.tif
source=9-1-17 Albany Molecular 2-TM#page16.tif
source=9-1-17 Albany Molecular 2-TM#page17.tif

source=9-1-17 Albany Molecular 2-TM#page18.tif
source=9-1-17 Albany Molecular 2-TM#page19.tif
source=9-1-17 Albany Molecular 2-TM#page20.tif
source=9-1-17 Albany Molecular 2-TM#page21.tif
source=9-1-17 Albany Molecular 2-TM#page22.tif
source=9-1-17 Albany Molecular 2-TM#page23.tif
source=9-1-17 Albany Molecular 2-TM#page24.tif
source=9-1-17 Albany Molecular 2-TM#page25.tif
source=9-1-17 Albany Molecular 2-TM#page26.tif
source=9-1-17 Albany Molecular 2-TM#page27.tif
source=9-1-17 Albany Molecular 2-TM#page28.tif
source=9-1-17 Albany Molecular 2-TM#page29.tif
source=9-1-17 Albany Molecular 2-TM#page30.tif
source=9-1-17 Albany Molecular 2-TM#page31.tif

SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) dated August 31, 2017, is among the Persons listed on the signature pages hereof (collectively, the “Grantors”) and Morgan Stanley Senior Funding, Inc., as collateral agent (the “Collateral Agent”) for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, UIC MERGER SUB, INC., a Delaware corporation, ALBANY MOLECULAR RESEARCH, INC., a Delaware corporation, and UIC PARENT CORPORATION, a Delaware corporation (“Holdings”), have entered into the Second Lien Credit Agreement dated as of August 31, 2017 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), with the lenders and financial institutions from time to time party thereto, MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent and Collateral Agent. Capitalized terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders from time to time, each Grantor has executed and delivered that certain Second Lien Security Agreement dated August 31, 2017 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent.

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed thereunder to execute this IP Security Agreement for recording with the USPTO and/or the USCO, as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

Grant of Security. Each Grantor hereby collaterally assigns and pledges to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, and each Grantor hereby grants to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a security interest in and to all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired by the undersigned (the “Collateral”):

all Patents, including the patents and patent applications set forth in Schedule A hereto (the “Patent Collateral”);

all Trademarks, including the trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, to the extent that, and solely during the period, if any, in which, the grant of a security interest therein or the assignment thereof would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law), together with the goodwill symbolized thereby (the “Trademark Collateral”);

all Copyrights, whether registered or unregistered, including, without limitation, the copyright registrations and applications set forth in Schedule C hereto (the "Copyright Collateral");

all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing;

provided that notwithstanding anything to the contrary contained in the foregoing clauses (i) through (vi), the security interest created hereby shall not extend to, and the term "Collateral" shall not include, any Excluded Property.

Security for Obligations. The grant of a security interest in, the Collateral by each Grantor under this IP Security Agreement secures the payment of all Secured Obligations of such Grantor now or hereafter existing under or in respect of the Loan Documents (as such Loan Documents may be amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to each Grantor, the payment of all amounts that constitute part of the Secured Obligations that would be owed by such Grantor to any Secured Party under the Loan Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks record this IP Security Agreement.

Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

Governing Law; Jurisdiction; Etc.

(1) THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF, BUT INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE COLLATERAL AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT OR THE RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.


(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN CLAUSE (b) OF THIS SECTION 6. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER

FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS IP SECURITY AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF SECTION 10.17 OF THE CREDIT AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

ALBANY MOLECULAR RESEARCH, INC.

By 

Name: William S. Marth

Title: President and Chief Executive Officer

[Project Capital – Second Lien Intellectual Property Security Agreement]

TRADEMARK
REEL: 006145 FRAME: 0301

AMRI BURLINGTON, INC.

By 
Name: William S. Marth
Title: President

[Project Capital -- Second Lien Intellectual Property Security Agreement]

TRADEMARK
REEL: 006145 FRAME: 0302

CEDARBURG PHARMACEUTICALS, INC.

By 
Name: William S. Marth
Title: President

[Project Capital -- Second Lien Intellectual Property Security Agreement]

TRADEMARK
REEL: 006145 FRAME: 0303


EUTICALS INC.

By 
Name: William S. Marth
Title: President


[Project Capital – Second Lien Intellectual Property Security Agreement]

TRADEMARK
REEL: 006145 FRAME: 0304

OSO Biopharmaceuticals Manufacturing, LLC
By its sole member: ALO Acquisition LLC

By: 
Name: Lori M. Henderson
Title: Manager

MORGAN STANLEY SENIOR FUNDING, INC.
as Collateral Agent

By: 
Name: Nehal Abdel Hakim
Title: Authorized Signatory

[Signature Page to Second Lien Intellectual Property Security Agreement]

TRADEMARK
REEL: 006145 FRAME: 0306

Schedule A

TITLE	APPLICATION NO.	APPLICATION FILING DATE	GRANT DATE	PATENT NO.	OWNER/NAME
VINCA DERIVATIVES	11/697,415	4/6/2007	11/25/2014	8,895,543	Albany Molecular Research, Inc.
VINCA DERIVATIVES	11/003,560	12/3/2004	7/3/2007	7,238,704	Albany Molecular Research, Inc.
VINCA DERIVATIVES	11/933,259	10/31/2007	6/29/2010	7,745,619	Albany Molecular Research, Inc.
VINCA DERIVATIVES					Albany Molecular Research, Inc.
VINORELBINE DERIVATIVES					Albany Molecular Research, Inc.
VINORELBINE DERIVATIVES	12/331,691	12/10/2008	11/30/2010	7,842,802	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	11/487,884	7/17/2006	6/7/2011	7,956,050	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN	12/598,882	5/8/2008	8/4/2015	9,096,546	Albany Molecular Research, Inc.
ARYLOXY- AND	12/598,912	5/8/2008	3/24/2015	8,987,252	Albany Molecular Research,

HETEROARYLOXY- SUBSTITUTED TETRAHYDROBENZAZEP HINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN						Inc.
ARYL- AND HETEROARYL- SUBSTITUTED TETRAHYDROBENZAZEPI NES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	12/917,066	11/1/2010	7/29/2014	8,791,101	Albany Molecular Research, Inc.	
ARYL- AND HETEROARYL- SUBSTITUTED TETRAHYDROBENZAZEPI NES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	14/304,833	6/13/2014	8/2/2016	9,403,776	Albany Molecular Research, Inc.	
PROCESS FOR PRODUCTION OF DELTA- 9- TETRAHYDROCANNABIN OL	13/108,651	5/16/2011	1/31/2012	8,106,244	Albany Molecular Research, Inc.	
EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF	12/898,271	10/5/2010	11/5/2013	8,575,186	Albany Molecular Research, Inc.	

2-AMINO BENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS	11/835,178	8/7/2007	1/4/2011	7,863,271	Albany Molecular Research, Inc.
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	12/351,561	1/9/2009	5/6/2014	8,716,308	Albany Molecular Research, Inc.
5-FUROPYRIDINONE SUBSTITUTED INDAZOLES	12/522,709	1/9/2008	1/24/2012	8,101,632	Albany Molecular Research, Inc.
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	12/473,940	5/28/2009	2/28/2012	8,124,600	Albany Molecular Research, Inc.
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	13/372,967	2/14/2012	8/6/2013	8,501,729	Albany Molecular Research, Inc.
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	13/941,304	7/12/2013	4/29/2014	8,710,047	Albany Molecular Research, Inc.
BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D	11/934,523	11/2/2007	8/24/2010	7,781,430	Albany Molecular Research, Inc.
ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF	12/884,650	9/17/2010	6/17/2014	8,754,054	Albany Molecular Research, Inc.
ANTI-INFECTIONAL COMPOUND					Albany Molecular Research, Inc.
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	14/223,151	3/24/2014	3/29/2016	9,296,743	Albany Molecular Research, Inc.
PIPERAZINONE-SUBSTITUTED	13/330,989	12/20/2011	4/15/2014	8,697,700	Albany Molecular Research, Inc.

TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF							
TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF	13/331,814	12/20/2011	3/31/2015	8,993,765	Albany Molecular Research, Inc.		
NITROGEN SUBSTITUTED BIARYL PURINE DERIVATIVES AS POTENT ANTIPROLIFERATIVE AGENTS	10/680,832	10/7/2003	9/27/2005	6,949,559	Albany Molecular Research, Inc.		
METHOD FOR ENZYMATIC GLYCOSYLATION OF INSULIN					Albany Molecular Research, Inc.		
CYCLOSPORINS	10/802,013	3/16/2004	5/26/2009	7,538,084	Albany Molecular Research, Inc.		
AZA-PYRAZOLOACRIDINES WITH POTENTIAL ANTITUMOR ACTIVITY					Albany Molecular Research, Inc.		
NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUOLINES THERAPEUTIC USE THEREOF	09/902,845	7/11/2001	8/1/2006	7,084,152	Albany Molecular Research, Inc.		
ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF	10/426,097	4/29/2003	11/3/2009	7,612,090	Albany Molecular Research, Inc.		
SYNTHESIS OF CF-101					Albany Molecular Research, Inc.		

COMPOUNDS WHICH INHIBIT SEROTONIN, DOPAMINE AND NOREPINEPHRINE TRANSPORT					
NOVEL R-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF					
NOVEL R-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF					
ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF					
SYSTEM AND METHOD OF DEVELOPING MOLECULAR MINI-FINGERPRINTS FOR IDENTIFYING COMPOUNDS HAVING SIMILAR ACTIVITY AND VIRTUAL SCREENING					Albany Molecular Research, Inc.
PROCESS FOR PREPARING MENTHADIENOL					
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	11/183,066	7/15/2005	6/2/2009	7,541,357	Albany Molecular Research, Inc.

NOVEL PROCESSES FOR STEREOSELECTIVE SYNTHESIS OF TRANS ISAsx247 [cyclosporin]	11/572,833	7/26/2005	9/21/2010	7,799,756	Albany Molecular Research, Inc.
NOVEL CYCLOSPORIN ANALOGUES AND THEIR PHARMACEUTICAL USES	11/232,292	9/21/2005	3/31/2009	7,511,013	Albany Molecular Research, Inc.
NOVEL CYCLOSPORIN ALKYNES AND THEIR UTILITY AS PHARMACEUTICAL AGENTS	12/046,854	3/12/2008	12/15/2009	7,632,807	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	12/252,823	10/16/2008	7/24/2012	8,227,486	Albany Molecular Research, Inc.
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	12/417,598	4/2/2009	8/7/2012	8,236,796	Albany Molecular Research, Inc.
CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZINE-3-AMINE	12/995,771	12/2/2010	5/21/2013	8,445,494	Albany Molecular Research, Inc.

TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR	12/995,776	6/4/2009	4/16/2013	8,420,811	Albany Molecular Research, Inc.
CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZINE-3-AMINE	13/845,919	3/18/2013	10/13/2015	9,156,812	Albany Molecular Research, Inc.
CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZINE-3-AMINE	14/841,024	8/31/2015	11/22/2016	9,498,476	Albany Molecular Research, Inc.
2,5-METHANO- and 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN	13/211,678	8/17/2011	6/2/2015	9,045,468	Albany Molecular Research, Inc.
SPIROINDANES AS MONOAMINE REUPTAKE INHIBITORS					Albany Molecular Research, Inc.
Synthesis of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridizin-3-amine					
SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC					Albany Molecular Research, Inc.

SYNDROME, COGNITION AND SCHIZOPHRENIA						
BENZOFURO[3,2-C]PYRIDINE AND AZEPINE ANALOGS AS SEROTONIN SUB TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA	13/352,864	1/18/2012	6/30/2015	9,067,949	Albany Molecular Research, Inc.	
AZINONE-SUBSTITUTED AZEPINOLINDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF	12/828,807	7/1/2010	1/28/2014	8,637,501	Albany Molecular Research, Inc.	
AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF	12/828,855	7/1/2010	1/14/2014	8,629,158	Albany Molecular Research, Inc.	
AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF	12/828,890	7/1/2010	12/31/2013	8,618,299	Albany Molecular Research, Inc.	
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	13/384,050	6/30/2010	4/29/2014	8,710,046	Albany Molecular Research, Inc.	
AZINONE-SUBSTITUTED AZABICYCLOALKANE-	12/828,955	7/1/2010	7/7/2015	9,073,925	Albany Molecular Research, Inc.	

INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF							Albany Molecular Research, Inc.
NOVEL AZACARBOLINES							Albany Molecular Research, Inc.
NOVEL AZACARBOLINES							Albany Molecular Research, Inc.
NOVEL CARBAZOLES							Albany Molecular Research, Inc.
SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF	13/052,171	3/21/2011	11/5/2013	8,575,114			Albany Molecular Research, Inc.
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUOLINES AND USE THEREOF	12/777,728	5/11/2010	5/19/2015	9,034,899			Albany Molecular Research, Inc.
7-([1,2,4]TRIAZOL[1,5-a]PYRIDINYL-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUOLINE AND USE THEREOF	12/777,776	5/11/2010	8/12/2014	8,802,696			Albany Molecular Research, Inc.
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOL[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUOLINE AND USE THEREOF	12/777,840	5/11/2010	8/26/2014	8,815,894			Albany Molecular Research, Inc.
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOL[1,5-	14/466,009	8/22/2014	11/3/2015	9,173,879			Albany Molecular Research, Inc.

a)PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF						
GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF	13/151,992	6/2/2011	6/2/2015	9,045,445	Albany Molecular Research, Inc.	
ARYL- AND HETEREROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN						
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF	14/593,750	1/9/2015	3/28/2017	9,604,960	Albany Molecular Research, Inc.	
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF	14/203,033	3/10/2014	6/2/2015	9,045,501	Albany Molecular Research, Inc.	
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	13/540,446	7/2/2012	6/3/2014	8,741,901	Albany Molecular Research, Inc.	

ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN							
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	14/268,753	5/2/2014	7/21/2015	9,085,531		Albany Molecular Research, Inc.	
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN	14/737,897	6/12/2015	11/22/2016	9,499,531		Albany Molecular Research, Inc.	
LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM	14/209,460	3/13/2014	5/31/2016	9,352,049		Albany Molecular Research, Inc.	
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	15/045,652	2/17/2016	5/16/2017	9,650,378		Albany Molecular Research, Inc.	

(1-AZINONE)- SUBSTITUTED PYRIDOINDOLES	15/477,984	4/3/2017				Albany Molecular Research, Inc.
PREPARATION OF DEXAMPHEFAMINE VINCA DERIVATIVES						Albany Molecular Research, Inc. Albany Molecular Research, Inc.
PROCESSES FOR PREPARING TETRAHYDROISOQUINOL INES	14/774,522	9/10/2015				Albany Molecular Research, Inc.
PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION	08/994,357	12-19-1997	11-30-1999	5,994,549		Albany Molecular Research, Inc.
PROCESS FOR ASEPTIC VACUUM FILLING AND STOPPERING OF LOW VISCOSITY LIQUIDS IN SYRINGES	11/657,814	1/25/2007	2/12/2008	7,328,549		AMRI BURLINGTON, INC.
SYRINGE LYOPHILIZATION METHODS AND APPARATUS						AMRI BURLINGTON, INC.
EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME	10/586,237	6/6/2008	5/22/2012	8,183,401		CEDARBURG PHARMACEUTICALS INC.
EXEMESTANE AND ITS INTERMEDIATES AND METHODS OF MAKING THE SAME	13/451,034	4/19/2012	9/24/2013	8,541,609		CEDARBURG PHARMACEUTICALS INC.
THE SAME						
PREPARATION OF AMIDES OF RETINOIC ACID VIA MIXED ANHYDRIDE AND MIXED CARBONATE	11/715,571	3/8/2007	1/22/2008	7,321,064		CEDARBURG PHARMACEUTICALS INC.

INTERMEDIATES						
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/356,282	1/20/2009	1/4/2011	7,863,452	Albany Molecular Research, Inc.	
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/956,601	11/30/2010	11/29/2011	8,067,605	Albany Molecular Research, Inc.	
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	10/212,854	8/5/2002	12/13/2005	6,974,872	Albany Molecular Research, Inc.	
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	09/754,786	1/4/2001	9/2/2003	6,613,907	Albany Molecular Research, Inc.	
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	10/638,841	8/11/2003	6/19/2007	7,232,908	Albany Molecular Research, Inc.	
PROCESS FOR THE PRODUCTION OF PIPERIDINE DERIVATIVES WITH MICROORGANISMS	11/624,096	1/17/2007	4/6/2010	7,691,615	Albany Molecular Research, Inc.	
METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE	15/431,572	2/13/2017			Albany Molecular Research, Inc.	
METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE	15/431,624	2/13/2017			Albany Molecular Research, Inc.	
OPIOID PRODRUGS OF HYDROCODONE AND HYDROMORPHONE						
LOW-BACKGROUND SCATTERING X-RAY DIFFRACTOMETER	13/302,474	11/22/2011	5/27/2014	8,737,564	AMRI SSCI, LLC	

DEVICES, SYSTEMS AND METHODS							
SYSTEM AND METHOD FOR MATCHING DIFFRACTION PATTERNS	10/635,113	8/6/2003	5/13/2008	7,372,941	AMRI SSCI, LLC		
SYSTEM AND METHOD FOR MATCHING DIFFRACTION PATTERNS	11/935,965	11/6/2007	5/11/2010	7,715,527	AMRI SSCI, LLC		
METHODS OF SEARCHING FOR SOLID FORMS AND SCREENING A SAMPLE ACCORDING TO ITS FORMS	09/752,857	12/28/2000	6/15/2004	6,750,064	AMRI SSCI, LLC Purdue Research Foundation		
METHODS FOR INDEXING SOLID FORMS OF COMPOUNDS	12/871,421	8/30/2010	11/5/2013	8,576,985	AMRI SSCI, LLC		
POLYMORPHS OF COCRYSTALS OF p-CUMARIC ACID: NICOTINAMIDE	14/607,186	1/28/2015	4/19/2016	9,314,459	AMRI SSCI, LLC		
POLYMORPHS OF COCRYSTALS OF p-CUMARIC ACID: NICOTINAMIDE	15/072,530	3/17/2016			AMRI SSCI, LLC		
METHODS OF GENERATING AND SCREENING FOR HIGH FREE ENERGY FORMS IN CAPILLARIES	09/752,788	12/28/2000	11/4/2003	6,642,060	AMRI SSCI, LLC Purdue Research Foundation		
METHODS OF GENERATING AND SCREENING FOR HIGH FREE ENERGY FORMS IN CAPILLARIES	10/688,123	10/17/2003	5/9/2006	7,041,169	AMRI SSCI, LLC Purdue Research Foundation		
NOVEL COCRYSTALLIZATION	10/763,987	1/21/2004	11/18/2008	7,452,555	AMRI SSCI, LLC		

COCRYSTALLIZATION	12/234,093	9/19/2008	7/3/2012	8,212,079	AMRI SSCI, LLC
PREPARATION OF MANNITOL MODIFICATION III	12/601,270	5/21/2008	3/5/2013	8,389,778	AMRI SSCI, LLC
SAMPLE HOLDER AND SAMPLE PREPARATION DEVICE	12/133,675	6/5/2008	9/13/2011	8,018,588	AMRI SSCI, LLC
METHODS OF MAKING COCRYSTALS	13/657,259	10/22/2012	9/1/2015	9,120,766	AMRI SSCI, LLC
SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND	12/888,052	9/22/2010	12/30/2014	8,920,559	AMRI SSCI, LLC
COCRYSTALS OF P-CUMARIC ACID	14/017,879	9/4/2013			AMRI SSCI, LLC
COCRYSTALS OF PROGESTERONE	14/017,397	9/4/2013	12/6/2016	9,512,166	AMRI SSCI, LLC
COCRYSTALS OF PROGESTERONE	15/333,691	10/25/2016			AMRI SSCI, LLC
NOVEL SYNTHESIS OF ERIBULIN MESSYLATE					AMRI SSCI, LLC
AMORPHOUS DISPERSIONS OF EPIGALLOCATECHIN GALLATE	62/535,075	7/20/2017			AMRI SSCI, LLC
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	08/576,068	12/21/1995	11/28/2000	6,153,754	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	12/483,002	06-11-2009	09-20-2011	8,022,220	Albany Molecular Research, Inc.
PROCESS FOR	12/951,644	11-22-2010	11-29-2011	8,067,6041	Albany Molecular Research,







1 Albany Molecular Research, Inc. intends to abandon this patent

PRODUCTION OF CAREBASTINE						Inc.
PROCESS FOR PRODUCTION OF CAREBASTINE	12/356,277	01-20-2009	12-28-2010	7,858,7982		Albany Molecular Research, Inc.
Synthesis of 2-AMINO BENZOXAZOLE compounds	12/604,491	10-23-2009	05-15-2012	8,178,666		Albany Molecular Research, Inc.
PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS	12/046,755	3/12/2008	07-31-2012	8,232,274		Albany Molecular Research, Inc./Merck Sharp & Dohme Corp.
PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION	08/456,273	5/31/1995	11/26/1996	5,578,610		Albany Molecular Research, Inc.
AROMATIC KETONES AND PROCESSES FOR THEIR PREPARATION	08/455,991	5/31/1995	12/3/1996	5,581,011		Albany Molecular Research, Inc.
PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION	08/382,425	2/2/1995	12/31/1996	5,589,487		Albany Molecular Research, Inc.
PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION	08/382,649	2/2/1995	5/12/1998	5,750,703		Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	08/575,344	12/21/1995	3/13/2001	6,201,124		Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,983	8/9/2000	9/3/2002	6,444,824		Albany Molecular Research, Inc.


2 Albany Molecular Research, Inc. intends to abandon this patent


PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,775	8/9/2000	9/10/2002	6,448,406	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/634,169	8/9/2000	9/17/2002	6,452,011	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	09/637,127	8/9/2000	10/1/2002	6,458,958	Albany Molecular Research, Inc.
PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES	11/521,820	9/15/2006	3/16/2010	7,678,915	Albany Molecular Research, Inc.
AZA-ACRIDINES WITH POTENTIAL ANTITUMOR ACTIVITY					Albany Molecular Research, Inc.
SUBSTANTIALLY PURE IBOGAMINE CONGENER ENANTIOMERS					Albany Molecular Research, Inc.

Schedule B

TRADEMARK	COUNTRY	APP. DATE	APP. NO.	REG. NO.	REG. DATE.	OWNER
	US	3/23/2016	86950416	5192656	4/25/2017	ALBANY MOLECULAR RESEARCH, INC.
	US	3/23/2016	86950456	5196964	5/2/2017	ALBANY MOLECULAR RESEARCH, INC.
	US	3/1/2007	77119,587	3,477,433	7/29/2008	ALBANY MOLECULAR RESEARCH, INC.
	US	8/2/2013	85/694,073	4,427,558	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
	US	8/2/2013	85/694,043	4,427,557	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
	US	10/02/2014	86/413,276	4911976	3/8/2016	ALBANY MOLECULAR RESEARCH, INC.



		US	10/02/2014	86/413,314	4911977	3/8/2016	ALBANY MOLECULAR RESEARCH, INC.
		US	7/13/2006	78/928,960	3,360,935	12/25/2007	ALBANY MOLECULAR RESEARCH, INC.
AMRI		US	8/2/2012	85/693,766	4,427,550	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
AMRI GLOBAL SMARTSOURCING		US	8/2/2012	85/693,714	4,427,548	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
AMRI SMARTSOURCING		US	8/2/2012	85/693,884	4,427,554	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
AMRI SMARTSOURCING		US	8/2/2012	85/693,856	4,427,553	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
SMARTSOURCING		US	8/2/2012	85/693,918	4,427,555	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.

SMARTSOURCING	US	8/2/2012	85/693,980	4,427,556	11/5/2013	ALBANY MOLECULAR RESEARCH, INC.
SSCI & Design  SSCI	US	12/22/2014	86/487,754	4,794,054	8/18/2015	AMRI SSCI, LLC
TRIADS	US	12/22/2014	86/487,769	4928687	3/29/2016	AMRI SSCI, LLC
WHERE CHEMISTRY MATTERS	US	10/16/2006	77/021,901	3,278,678	8/14/2007	AMRI SSCI, LLC
design	US	12/9/1997	75402494	2306495	1/4/2000	CEDARBURG PHARMACEUTICALS INC.
OSOBIO AN INJECTABLES CMO	US	8/4/2008	77537890	3901048	1/4/2011	Oso Biopharmaceuticals, LLC
CEDARBURG LABORATORIES	US Wisconsin				7/5/2000	Cedarburg Pharmaceuticals, LLC

Schedule C

None.